Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
Maccura Biotechnology Co.Ltd (300463.SZ)
Chengdu, CN
Maccura Biotechnology Co. Ltd. is an enterprise actively involved in the entire process of in vitro diagnostic (IVD) products, from their initial conceptualization and refinement (research and development) to mass production and market delivery. The company also extends related support services, catering to clientele within China and across global territories. Its diverse portfolio features immunoassay solutions, exemplified by chemiluminescence analyzers and their accompanying reagents. In the domain of clinical chemistry, Maccura furnishes reagents vital for evaluating a broad spectrum of physiological indicators, including hepatic and renal function, glucose metabolism, iron levels, specialized proteins, cardiac health, lipid profiles, and coagulation. Moreover, the firm supplies sophisticated clinical laboratory instrumentation, notably automatic hematology systems and both automated and semi-automated coagulation analyzers. The company's offerings further extend to include diagnostic tools for SARS-CoV-2 (COVID-19), such as nucleic acid detection kits and other related items. Additional products consist of glucometers, point-of-care testing (POCT) devices like fluorescence immunoassay analyzers and colloidal gold rapid test kits, molecular diagnostics (e.g., PCR kits), and a variety of pathology supplies. Maccura Biotechnology Co. Ltd. was established in 1994 and maintains its principal operations in Chengdu, China.
No mergers or acquisitions recorded for this company.
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| -2.04% | +0.76% | -2.32% | -9.84% | -13.32% | -5.81% | -11.58% | -37.22% | -77.90% | -61.01% | -21.46% |
Revenue flow
Revenue by geography
Revenue by segment
Revenue composition
By product
By geography
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
DCF figures are point estimates: small changes in growth or discount-rate assumptions move them materially. Read them as a reference, not a precise target.
| Rating | 2026-05 | Change |
|---|---|---|
| Strong Buy | 0 | 0 |
| Buy | 2 | 0 |
| Hold | 0 | 0 |
| Sell | 0 | 0 |
| Strong Sell | 0 | 0 |
-
Revenue growth Medical - Diagnostics & Research: +7.9%-15.5% Q1'26: -6.9% (vs Q1'25)
-
EPS growth Medical - Diagnostics & Research: +30.8%-128.4% Q1'26: -62.0% (vs Q1'25)
-
FCF margin FCF growth · Medical - Diagnostics & Research: +32.2%+10.3% Q1'26: +4.8% (vs Q1'25)
-
EBIT margin Medical - Diagnostics & Research: +9.6%-1.5% Q1'26: +3.1% (vs Q1'25)
-
ROIC Medical - Diagnostics & Research: +5.2%-0.5% Q1'26: +0.7% (vs Q1'25)
-
Share dilution Medical - Diagnostics & Research: 0.0%-1.3% ★ Q1'26: -1.4% (vs Q1'25)
-
Debt / EBITDA Net debt/EBITDA · Medical - Diagnostics & Research: -0.13×2.89× Q1'26: 13.53× (vs Q1'25)
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
| Metric |
Dec 2015 actual |
Dec 2016 actual |
Dec 2017 actual |
Dec 2018 actual |
Dec 2019 actual |
Dec 2020 actual |
Dec 2021 actual |
Dec 2022 actual |
Dec 2023 actual |
Dec 2024 actual |
Dec 2025 actual |
Dec 2026 1 Rev. Ana. 1 EPS Ana. |
Dec 2027 2 Rev. Ana. 2 EPS Ana. |
Dec 2028 1 Rev. Ana. 1 EPS Ana. |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue |
1.07B
est: 1.14B (-6.6%)
|
1.49B
est: 1.39B (+7.3%)
|
1.97B
est: 1.91B (+2.9%)
|
2.69B
est: 2.56B (+5.0%)
|
3.22B
est: 3.22B (0.0%)
|
3.70B
est: 3.68B (+0.8%)
|
3.98B
est: 4.48B (-11.2%)
|
3.61B
est: 3.67B (-1.6%)
|
2.90B
est: 2.79B (+3.6%)
|
2.55B
est: 2.98B (-14.4%)
|
2.15B
est: 2.33B (-7.4%)
|
2.20B
2.03B – 2.38B
-5.4% YoY
|
2.33B
1.99B – 2.66B
+5.5% YoY
|
2.45B
2.25B – 2.64B
+5.2% YoY
|
| EBITDA |
352.52M
est: 328.81M (+7.2%)
|
449.22M
est: 399.87M (+12.3%)
|
604.30M
est: 551.56M (+9.6%)
|
756.32M
est: 737.15M (+2.6%)
|
915.32M
est: 928.78M (-1.4%)
|
1.23B
est: 1.06B (+16.3%)
|
1.46B
est: 1.29B (+13.3%)
|
1.07B
est: 1.06B (+1.1%)
|
626.55M
est: 706.93M (-11.4%)
|
582.02M
est: 753.24M (-22.7%)
|
338.02M
est: 589.03M (-42.6%)
|
557.41M
513.31M – 601.50M
-5.4% YoY
|
588.27M
503.96M – 672.59M
+5.5% YoY
|
619.14M
570.16M – 668.13M
+5.2% YoY
|
| EBIT |
299.46M
est: 235.55M (+27.1%)
|
377.09M
est: 286.46M (+31.6%)
|
504.60M
est: 395.13M (+27.7%)
|
634.53M
est: 528.08M (+20.2%)
|
759.82M
est: 665.36M (+14.2%)
|
1.03B
est: 758.68M (+35.3%)
|
1.24B
est: 925.07M (+34.1%)
|
815.54M
est: 757.03M (+7.7%)
|
331.60M
est: 413.35M (-19.8%)
|
262.16M
est: 440.43M (-40.5%)
|
-32.90M
est: 344.42M (-109.6%)
|
325.92M
300.14M – 351.71M
-5.4% YoY
|
343.97M
294.67M – 393.28M
+5.5% YoY
|
362.02M
333.38M – 390.66M
+5.2% YoY
|
| Net Income |
251.04M
est: 289.96M (-13.4%)
|
312.02M
est: 343.05M (-9.0%)
|
374.13M
est: 428.81M (-12.8%)
|
444.93M
est: 500.28M (-11.1%)
|
525.26M
est: 581.96M (-9.7%)
|
793.92M
est: 863.75M (-8.1%)
|
956.60M
est: 1.08B (-11.8%)
|
708.18M
est: 802.49M (-11.8%)
|
312.62M
est: 339.51M (-7.9%)
|
126.81M
est: 429.31M (-70.5%)
|
-35.83M
est: 211.63M (-116.9%)
|
96.75M
86.79M – 106.70M
-54.3% YoY
|
151.17M
80.41M – 221.92M
+56.3% YoY
|
199.54M
179.02M – 220.06M
+32.0% YoY
|
| SGA |
279.03M
est: 264.23M (+5.6%)
|
397.34M
est: 321.34M (+23.7%)
|
423.20M
est: 443.24M (-4.5%)
|
576.20M
est: 592.38M (-2.7%)
|
686.23M
est: 746.38M (-8.1%)
|
636.98M
est: 851.06M (-25.2%)
|
756.10M
est: 1.04B (-27.1%)
|
749.75M
est: 849.21M (-11.7%)
|
805.79M
est: 713.98M (+12.9%)
|
789.95M
est: 760.75M (+3.8%)
|
628.76M
est: 594.90M (+5.7%)
|
562.96M
518.42M – 607.50M
-5.4% YoY
|
594.14M
508.98M – 679.30M
+5.5% YoY
|
625.31M
575.84M – 674.78M
+5.2% YoY
|
| EPS |
0.45
est: 0.47 (-4.9%)
|
0.56
est: 0.56 (+0.0%)
|
0.67
est: 0.70 (-4.3%)
|
0.80
est: 0.82 (-2.0%)
|
0.95
est: 0.95 (+0.0%)
|
1.43
est: 1.41 (+1.4%)
|
1.73
est: 1.77 (-2.3%)
|
1.17
est: 1.31 (-10.7%)
|
0.51
est: 0.56 (-8.9%)
|
0.21
est: 0.71 (-70.4%)
|
-0.06
est: 0.35 (-116.9%)
|
0.16
0.14 – 0.18
-54.3% YoY
|
0.25
0.13 – 0.37
+56.3% YoY
|
0.33
0.30 – 0.36
+32.0% YoY
|
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-08 | C+ | 2/5 | 3/5 | 1/5 | 1/5 | 2/5 | 1/5 | 4/5 |
| 2026-05-07 | C+ | 2/5 | 3/5 | 1/5 | 1/5 | 2/5 | 1/5 | 4/5 |
| 2026-05-06 | C+ | 2/5 | 3/5 | 1/5 | 1/5 | 2/5 | 1/5 | 4/5 |
| 2026-04-30 | C+ | 2/5 | 3/5 | 1/5 | 1/5 | 2/5 | 1/5 | 4/5 |
| 2026-04-29 | C+ | 2/5 | 3/5 | 1/5 | 1/5 | 2/5 | 1/5 | 4/5 |
| 2026-04-28 | C+ | 2/5 | 3/5 | 1/5 | 1/5 | 2/5 | 1/5 | 4/5 |
| 2026-04-27 | C+ | 2/5 | 3/5 | 1/5 | 1/5 | 2/5 | 1/5 | 4/5 |
| 2026-04-24 | C+ | 2/5 | 3/5 | 1/5 | 1/5 | 2/5 | 1/5 | 4/5 |
| 2026-04-23 | C+ | 2/5 | 3/5 | 1/5 | 1/5 | 2/5 | 1/5 | 4/5 |
| 2026-04-22 | C+ | 2/5 | 3/5 | 1/5 | 1/5 | 2/5 | 1/5 | 4/5 |
| 2026-04-21 | C+ | 2/5 | 3/5 | 1/5 | 1/5 | 2/5 | 1/5 | 4/5 |
| 2026-04-20 | C+ | 2/5 | 3/5 | 1/5 | 1/5 | 2/5 | 1/5 | 4/5 |
| 2026-04-17 | C+ | 2/5 | 3/5 | 1/5 | 1/5 | 2/5 | 1/5 | 4/5 |
| 2026-04-16 | C+ | 2/5 | 3/5 | 1/5 | 1/5 | 2/5 | 1/5 | 4/5 |
Owner Earnings
Ownership Overview
Ownership breakdown not available.
No beneficial ownership filings recorded.
Institutional Activity (13F)
Institutional history not available.
Top holders not available.
ETF Ownership
| # | ETF | Weight | Est. AUM exposure | TER |
|---|---|---|---|---|
| 1 | State Street SPDR S&P Emerging Markets Small Cap ETF EWX | 0.01% | 39.8K | 0.65% |
| 2 | State Street SPDR S&P China ETF GXC | 0.00% | 13.8K | 0.59% |
| 3 | Vanguard FTSE All-World ex-US Small-Cap ETF VSS | 0.00% | 190.3K | 0.06% |
| 4 | Dimensional - Emerging Markets Core Equity 2 ETF DFEM | 0.00% | 114.2K | 0.39% |
| 5 | Vanguard FTSE Emerging Markets Shares ETF VGE.AX | 0.00% | 14.3K | 0.48% |
| 6 | Vanguard FTSE Emerging Markets All Cap Index ETF VEE.TO | 0.00% | 32.2K | 0.26% |
| 7 | Vanguard ESG International Stock ETF VSGX | 0.00% | 66.9K | 0.10% |
| 8 | Vanguard FTSE Emerging Markets ETF VWO | 0.00% | 1.59M | 0.06% |
| 9 | Dimensional - Emerging Core Equity Market ETF DFAE | 0.00% | 57.7K | 0.29% |
| 10 | Dimensional World ex U.S. Core Equity 2 ETF DFAX | 0.00% | 57.4K | 0.28% |
Insider Activity
No insider activity available.
Insider history not available.
No recent insider transactions.
Executive team
Executive compensation
Executive compensation not available.
No CEO compensation history available.
Proxy statements
No proxy statements available for this company yet.
Recent SEC filings
No SEC filings available for this company yet.
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Ping You | Accounting Supervisor | — | — |
| Ping Yu | Administrative Director & Manager of Human Resource Department | — | female |
| Shan Yin | Chief Financial Officer & Director | — | female |
| Shengguo Xu | Director of Marketing | — | male |
| Tengxiang Long | Director of R&D - Reagents | — | male |
| Wei Shi | Secretary & Director of Strategic Investment | — | female |
| Weijia Wang | Director of R&D - Instrumentation | — | male |
| Wu Mingjian | GM & Director | — | male |
| Zhen Wang | Production Director | — | male |
No data available for this company.
No Senate trading activity found for this company.
No House trading activity found for this company.
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for 300463.SZ
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
